ZA200704888B - Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases - Google Patents
Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinasesInfo
- Publication number
- ZA200704888B ZA200704888B ZA200704888A ZA200704888A ZA200704888B ZA 200704888 B ZA200704888 B ZA 200704888B ZA 200704888 A ZA200704888 A ZA 200704888A ZA 200704888 A ZA200704888 A ZA 200704888A ZA 200704888 B ZA200704888 B ZA 200704888B
- Authority
- ZA
- South Africa
- Prior art keywords
- pyrazolopyrazines
- pyrrolopyrazines
- inhibitors
- useful
- protein kinases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Hematology (AREA)
- Virology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Transplantation (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63011504P | 2004-11-22 | 2004-11-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200704888B true ZA200704888B (en) | 2009-02-25 |
Family
ID=35953926
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200704888A ZA200704888B (en) | 2004-11-22 | 2005-11-22 | Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases |
Country Status (14)
Country | Link |
---|---|
US (3) | US20060122185A1 (xx) |
EP (3) | EP2316835A1 (xx) |
JP (3) | JP2008520738A (xx) |
KR (1) | KR20070089201A (xx) |
CN (1) | CN101098872B (xx) |
AU (2) | AU2005309566A1 (xx) |
CA (2) | CA2587894A1 (xx) |
IL (1) | IL183318A0 (xx) |
MX (1) | MX2007006103A (xx) |
NO (1) | NO20073140L (xx) |
NZ (1) | NZ555566A (xx) |
RU (1) | RU2394825C2 (xx) |
WO (2) | WO2006058120A1 (xx) |
ZA (1) | ZA200704888B (xx) |
Families Citing this family (129)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HN2005000795A (es) * | 2004-10-15 | 2010-08-19 | Aventis Pharma Inc | Pirimidinas como antagonistas del receptor de prostaglandina d2 |
CN101228161B (zh) * | 2005-05-20 | 2012-10-10 | 沃泰克斯药物股份有限公司 | 适用作蛋白激酶抑制剂的吡咯并吡啶类 |
KR20080040027A (ko) | 2005-09-02 | 2008-05-07 | 아스테라스 세이야쿠 가부시키가이샤 | Rock 억제제로서 아미드 유도체 |
US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
WO2007076423A2 (en) * | 2005-12-22 | 2007-07-05 | Smithkline Beecham Corporation | INHIBITORS OF Akt ACTIVITY |
BRPI0722364A2 (pt) | 2006-01-17 | 2011-08-16 | Vertex Pharma | azaindóis, composição farmacêutica e usos dos referidos compostos |
JP2009544625A (ja) * | 2006-07-20 | 2009-12-17 | メーメット・カーラマン | Rhoキナーゼのベンゾチオフェン阻害剤 |
CL2007002617A1 (es) * | 2006-09-11 | 2008-05-16 | Sanofi Aventis | Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto. |
JP2010505962A (ja) | 2006-10-09 | 2010-02-25 | 武田薬品工業株式会社 | キナーゼ阻害剤 |
EP2815750A1 (en) | 2006-12-21 | 2014-12-24 | Vertex Pharmaceuticals Incorporated | 5-cyano-4-(pyrrolo [2,3b] pyridine-3-yl)-pyrimidine derivatives useful as protein kinase inhibitors |
MX2009009793A (es) | 2007-03-14 | 2009-10-16 | Ranbaxy Lab Ltd | Derivados de pirazolo (3,4-b) piridina como inhibidores de fosfodiesterasa. |
AU2008228768A1 (en) * | 2007-03-22 | 2008-09-25 | Vertex Pharmaceuticals Incorporated | N-heterocyclic compounds useful as inhibitors of Janus Kinases |
ATE522534T1 (de) * | 2008-02-25 | 2011-09-15 | Hoffmann La Roche | Pyrrolopyrazin-kinasehemmer |
ATE522536T1 (de) * | 2008-02-25 | 2011-09-15 | Hoffmann La Roche | Pyrrolopyrazin-kinasehemmer |
MX2010009023A (es) * | 2008-02-25 | 2010-09-07 | Hoffmann La Roche | Inhibidores de cinasas de pirrolopirazina. |
CA2713710A1 (en) * | 2008-02-25 | 2009-09-03 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine kinase inhibitors |
CN101945877B (zh) * | 2008-02-25 | 2013-07-03 | 霍夫曼-拉罗奇有限公司 | 吡咯并吡嗪激酶抑制剂 |
WO2009145814A2 (en) * | 2008-03-10 | 2009-12-03 | Vertex Pharmaceuticals Incorporated | Pyrimidines and pyridines useful as inhibitors of protein kinases |
JP5767965B2 (ja) * | 2008-06-10 | 2015-08-26 | プレキシコン インコーポレーテッドPlexxikon Inc. | キナーゼを調節する5h−ピロロ[2,3−b]ピラジン誘導体、およびその適応症 |
US8426411B2 (en) | 2008-06-10 | 2013-04-23 | Abbott Laboratories | Tricyclic compounds |
WO2010011768A1 (en) * | 2008-07-23 | 2010-01-28 | Vertex Pharmaceuticals Incorporated | Tri-cyclic pyrazolopyridine kinase inhibitors |
CA2731451A1 (en) * | 2008-07-23 | 2010-01-28 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridine kinase inhibitors |
JP5542287B2 (ja) * | 2008-07-23 | 2014-07-09 | バーテックス ファーマシューティカルズ インコーポレイテッド | ピラゾロピリジンキナーゼ阻害剤 |
CN102170883A (zh) * | 2008-08-05 | 2011-08-31 | 雅培制药有限公司 | 可用作蛋白激酶抑制剂的化合物 |
RU2011123647A (ru) | 2008-11-10 | 2012-12-20 | Вертекс Фармасьютикалз Инкорпорейтед | Соединения, полезные в качестве ингибиторов atr киназы |
AU2009324210A1 (en) * | 2008-12-05 | 2010-06-10 | F. Hoffmann-La Roche Ag | Pyrrolopyrazinyl urea kinase inhibitors |
CA3013000C (en) | 2008-12-19 | 2022-12-13 | Vertex Pharmaceuticals Incorporated | Pyrazine derivatives useful as inhibitors of atr kinase |
GEP20156325B (en) | 2009-06-17 | 2015-07-10 | Vertex Pharma | Inhibitors of influenza viruses replication |
ES2432029T3 (es) | 2009-07-15 | 2013-11-29 | Abbvie Inc. | Inhibidores de quinasas de pirrolopiridina |
CA2767091A1 (en) * | 2009-07-15 | 2011-01-20 | Abbott Laboratories | Pyrrolopyrazine inhibitors of kinases |
DE102009060175A1 (de) * | 2009-12-23 | 2011-06-30 | Merck Patent GmbH, 64293 | Pyrrolo[2,3-d] pyrazin-7-yl-pyrimidin-Verbindungen |
WO2011094283A1 (en) * | 2010-01-27 | 2011-08-04 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridine kinase inhibitors |
US9067932B2 (en) * | 2010-01-27 | 2015-06-30 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridine kinase inhibitors |
AU2011209649A1 (en) * | 2010-01-27 | 2012-08-09 | Vertex Pharmaceuticals Incorporated | Pyrazolopyrazine kinase inhibitors |
CN101817823B (zh) * | 2010-03-31 | 2012-09-12 | 上海毕得医药科技有限公司 | 4,7-二氮杂吲哚及其5位取代物的制备方法 |
AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
EP2560488B1 (en) | 2010-04-23 | 2015-10-28 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
SG185524A1 (en) | 2010-05-12 | 2012-12-28 | Vertex Pharma | Compounds useful as inhibitors of atr kinase |
EP2568984A1 (en) | 2010-05-12 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EP2569286B1 (en) | 2010-05-12 | 2014-08-20 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
EP2569287B1 (en) | 2010-05-12 | 2014-07-09 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
WO2011143419A1 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Pyrazines useful as inhibitors of atr kinase |
CA2798760A1 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | 2-aminopyridine derivatives useful as inhibitors of atr kinase |
EP2585468A1 (en) * | 2010-06-23 | 2013-05-01 | Vertex Pharmaceuticals Incorporated | Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase |
WO2012018909A1 (en) * | 2010-08-04 | 2012-02-09 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
DE102010049877A1 (de) * | 2010-11-01 | 2012-05-03 | Merck Patent Gmbh | 7-((1,2,3)Triazol-4-yl)-pyrrolo(2,3) pyrazinderivate |
MX2013006836A (es) | 2010-12-16 | 2013-09-26 | Vertex Pharma | Inhibidores de la replicacion de los virus de la influenza. |
WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
US11466017B2 (en) | 2011-03-10 | 2022-10-11 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
JP2014510151A (ja) | 2011-04-05 | 2014-04-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ(trakinase)阻害剤として有用なアミノピラジン化合物 |
US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
US8822469B2 (en) | 2011-06-22 | 2014-09-02 | Vertex Pharmaceuticals Incorporated | Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase |
JP2014522818A (ja) | 2011-06-22 | 2014-09-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
EP2723746A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
CA2850564A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
US8853217B2 (en) | 2011-09-30 | 2014-10-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
EP2751088B1 (en) | 2011-09-30 | 2016-04-13 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
WO2013049726A2 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Processes for making compounds useful as inhibitors of atr kinase |
CA2850491C (en) | 2011-09-30 | 2020-10-27 | Vertex Pharmaceuticals Incorporated | Treating pancreatic cancer and non-small cell lung cancer with atr inhibiors |
US8841450B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
JP2015502925A (ja) | 2011-11-09 | 2015-01-29 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atrキナーゼの阻害剤として有用なピラジン化合物 |
WO2013071088A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
WO2013071090A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EP2776429A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
MX358818B (es) | 2012-04-05 | 2018-09-05 | Vertex Pharma | Compuestos utiles como inhibidores de cinasa ataxia telangiectasia mutada y rad3 relacionados (atr) y terapias de combinacion de estos. |
WO2013184985A1 (en) * | 2012-06-08 | 2013-12-12 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
PT3495367T (pt) | 2012-06-13 | 2020-11-12 | Incyte Holdings Corp | Compostos tricíclicos substituídos como inibidores de fgfr |
WO2014004863A2 (en) * | 2012-06-27 | 2014-01-03 | Alzheimer's Institute Of America, Inc. | Compounds, compositions, and therapeutic uses thereof |
WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
WO2014055756A1 (en) | 2012-10-04 | 2014-04-10 | Vertex Pharmaceuticals Incorporated | Method for measuring atr inhibition mediated increases in dna damage |
KR20150068956A (ko) * | 2012-10-16 | 2015-06-22 | 에프. 호프만-라 로슈 아게 | 세린/트레오닌 키나아제 억제제 |
US8912198B2 (en) | 2012-10-16 | 2014-12-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
ES2946360T3 (es) | 2012-12-07 | 2023-07-17 | Vertex Pharma | Pirazolo[1,5-a]pirimidinas útiles como inhibidores de ATR quinasa para el tratamiento de enfermedades de cáncer |
EP2928893A1 (en) * | 2012-12-10 | 2015-10-14 | F. Hoffmann-La Roche AG | Novel bi-ring phenyl-pyridines/pyrazines for the treatment of cancer |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
WO2014143240A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
TWI715901B (zh) | 2013-04-19 | 2021-01-11 | 美商英塞特控股公司 | 作為fgfr抑制劑之雙環雜環 |
GB2515785A (en) * | 2013-07-03 | 2015-01-07 | Redx Pharma Ltd | Compounds |
US9718818B2 (en) | 2013-08-22 | 2017-08-01 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
RS59144B1 (sr) | 2013-11-13 | 2019-09-30 | Vertex Pharma | Inhibitori replikacije virusa influence |
EP3421468B1 (en) | 2013-11-13 | 2020-11-04 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
RU2687276C2 (ru) | 2013-12-06 | 2019-05-13 | Вертекс Фармасьютикалз Инкорпорейтед | Соединения, пригодные для использования в качестве ингибиторов atr киназы |
LT3152212T (lt) | 2014-06-05 | 2020-05-11 | Vertex Pharmaceuticals Inc. | Radioaktyviai žymėti 2-amino-6-fluor-n-[5-fluor-piridin-il]- pirazolo[1,5-a]pirimidin-3-karboksamido junginio dariniai, naudingi kaip atr kinazės inhibitoriai, minėto junginio gamybos būdas ir jo skirtingos kietos formos |
SG11201610500WA (en) | 2014-06-17 | 2017-01-27 | Vertex Pharma | Method for treating cancer using a combination of chk1 and atr inhibitors |
WO2016026078A1 (en) * | 2014-08-19 | 2016-02-25 | Changzhou Jiekai Pharmatech Co., Ltd. | Heterocyclic compounds as erk inhibitors |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
CN113004278B (zh) | 2015-02-20 | 2023-07-21 | 因赛特控股公司 | 作为fgfr抑制剂的双环杂环 |
WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
WO2016183116A1 (en) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Methods of preparing inhibitors of influenza viruses replication |
WO2016183120A1 (en) | 2015-05-13 | 2016-11-17 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
WO2016192063A1 (en) * | 2015-06-03 | 2016-12-08 | Changzhou Jiekai Pharmatech Co. Ltd | Heterocyclic compounds as erk inhibitors |
CN106336413B (zh) * | 2015-07-09 | 2021-04-20 | 广东东阳光药业有限公司 | 作为jak抑制剂的化合物及其用途 |
CA3000684A1 (en) | 2015-09-30 | 2017-04-06 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna damaging agents and atr inhibitors |
WO2017064119A1 (en) | 2015-10-13 | 2017-04-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion |
EP4088719A1 (en) | 2015-10-13 | 2022-11-16 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion |
US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11773106B2 (en) | 2015-10-16 | 2023-10-03 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
EP3362455A1 (en) | 2015-10-16 | 2018-08-22 | AbbVie Inc. | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
CN109475531B (zh) | 2016-05-31 | 2021-08-17 | 得克萨斯州立大学董事会 | Ptpn11的杂环抑制剂 |
EP3504204A4 (en) | 2016-08-26 | 2020-05-27 | Lycera Corporation | INDAZOLYL-L, 2,4-THIADIAZOLAMINE AND RELATED COMPOUNDS FOR INHIBITING RHO-ASSOCIATED PROTEIN KINASES AND FOR TREATING DISEASES |
AU2017376541B2 (en) * | 2016-12-15 | 2021-08-05 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication and uses thereof |
WO2018151830A1 (en) * | 2017-02-17 | 2018-08-23 | Fronthera U.S. Pharmaceuticals Llc | Pyridinyl based apoptosis signal-regulation kinase inhibitors |
CN108948002A (zh) * | 2017-05-19 | 2018-12-07 | 厦门大学 | 五元并六元氮杂芳环类化合物、其制备方法、药用组合物及其应用 |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
KR20200127005A (ko) | 2018-03-02 | 2020-11-09 | 오쓰까 세이야꾸 가부시키가이샤 | 약제학적 화합물 |
JP6557436B1 (ja) | 2018-03-12 | 2019-08-07 | アッヴィ・インコーポレイテッド | チロシンキナーゼ2媒介性シグナル伝達の阻害剤 |
AU2019263294B2 (en) * | 2018-05-02 | 2024-03-21 | Navire Pharma, Inc. | Substituted heterocyclic inhibitors of PTPN11 |
CR20200591A (es) | 2018-05-04 | 2021-03-31 | Incyte Corp | Sales de un inhibidor de fgfr |
WO2019213544A2 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
PE20211050A1 (es) | 2018-08-10 | 2021-06-04 | Navire Pharma Inc | Inhibidores de ptpn11 |
US11926633B2 (en) | 2018-08-31 | 2024-03-12 | Suzhou Pengxu Pharmatech Co., Ltd | Synthesis methods for upadacitinib and intermediate thereof |
WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
MX2021015500A (es) | 2019-06-14 | 2022-02-10 | Janssen Pharmaceutica Nv | Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b. |
TW202116773A (zh) * | 2019-07-04 | 2021-05-01 | 英屬開曼群島商百濟神州有限公司 | 作為HPK1抑制劑之吡咯并[2,3-b]吡及其用途 |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
TW202128685A (zh) | 2019-10-14 | 2021-08-01 | 美商英塞特公司 | 作為fgfr抑制劑之雙環雜環 |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
CA3162010A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
EP4387972A1 (en) | 2021-08-20 | 2024-06-26 | Biomea Fusion, Inc. | Crystalline form of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo -2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, an irreversible menin-mll inhibitor for the treatment of cancer |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2648372B2 (ja) * | 1989-09-18 | 1997-08-27 | キヤノン株式会社 | インクジェット記録装置 |
BR0104424A (pt) * | 2000-02-05 | 2002-01-08 | Vertex Pharma | Composições de pirazol úteis como inibidores de erk |
MY130778A (en) * | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
GB0115109D0 (en) * | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
JP2004538228A (ja) | 2001-06-22 | 2004-12-24 | ビーエーエスエフ アクチェンゲゼルシャフト | 特定の長さ幅比を有する棒状アパタイト結晶 |
WO2003024969A1 (en) | 2001-09-14 | 2003-03-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
GB0206860D0 (en) * | 2002-03-22 | 2002-05-01 | Glaxo Group Ltd | Compounds |
CA2495216A1 (en) * | 2002-08-12 | 2004-02-19 | Sugen, Inc. | 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors |
DE60336576D1 (de) * | 2002-10-30 | 2011-05-12 | Merck Sharp & Dohme | Hemmer der akt aktivität |
KR20050088283A (ko) * | 2002-10-30 | 2005-09-05 | 버텍스 파마슈티칼스 인코포레이티드 | Rock 및 기타 단백질 키나제의 억제제로서 유용한조성물 |
TWI339206B (en) | 2003-09-04 | 2011-03-21 | Vertex Pharma | Compositions useful as inhibitors of protein kinases |
EP1737865A1 (en) * | 2004-02-27 | 2007-01-03 | F.Hoffmann-La Roche Ag | Fused derivatives of pyrazole |
MXPA06009462A (es) | 2004-02-27 | 2007-03-15 | Hoffmann La Roche | Derivados pirazolo heteroaril fusionados. |
US7763843B2 (en) | 2004-03-01 | 2010-07-27 | Stanton Magnetics, Inc. | Optical navigation system for rotary control based non-contact controller |
AU2005236002A1 (en) * | 2004-04-02 | 2005-11-03 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of rock and other protein kinases |
AU2005269387A1 (en) * | 2004-07-27 | 2006-02-09 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
CN101389626A (zh) * | 2004-07-27 | 2009-03-18 | Sgx药物公司 | 稠环杂环激酶调节剂 |
-
2005
- 2005-11-22 WO PCT/US2005/042537 patent/WO2006058120A1/en active Application Filing
- 2005-11-22 WO PCT/US2005/042455 patent/WO2006058074A1/en active Application Filing
- 2005-11-22 EP EP10185488A patent/EP2316835A1/en not_active Withdrawn
- 2005-11-22 US US11/285,516 patent/US20060122185A1/en not_active Abandoned
- 2005-11-22 EP EP05825542A patent/EP1814883A1/en not_active Withdrawn
- 2005-11-22 EP EP05825395A patent/EP1814882A1/en not_active Withdrawn
- 2005-11-22 NZ NZ555566A patent/NZ555566A/en not_active IP Right Cessation
- 2005-11-22 ZA ZA200704888A patent/ZA200704888B/xx unknown
- 2005-11-22 CN CN2005800460428A patent/CN101098872B/zh not_active Expired - Fee Related
- 2005-11-22 CA CA002587894A patent/CA2587894A1/en not_active Abandoned
- 2005-11-22 CA CA002587926A patent/CA2587926A1/en not_active Abandoned
- 2005-11-22 MX MX2007006103A patent/MX2007006103A/es active IP Right Grant
- 2005-11-22 JP JP2007543441A patent/JP2008520738A/ja active Pending
- 2005-11-22 KR KR1020077014367A patent/KR20070089201A/ko not_active Application Discontinuation
- 2005-11-22 US US11/285,497 patent/US7795259B2/en not_active Expired - Fee Related
- 2005-11-22 AU AU2005309566A patent/AU2005309566A1/en not_active Abandoned
- 2005-11-22 JP JP2007543468A patent/JP2008520745A/ja active Pending
- 2005-11-22 RU RU2007123360/04A patent/RU2394825C2/ru not_active IP Right Cessation
- 2005-11-22 AU AU2005309616A patent/AU2005309616A1/en not_active Abandoned
-
2007
- 2007-05-20 IL IL183318A patent/IL183318A0/en unknown
- 2007-06-20 NO NO20073140A patent/NO20073140L/no not_active Application Discontinuation
-
2008
- 2008-09-12 JP JP2008235263A patent/JP2009024024A/ja active Pending
-
2010
- 2010-07-30 US US12/847,136 patent/US8372835B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
KR20070089201A (ko) | 2007-08-30 |
WO2006058074A1 (en) | 2006-06-01 |
CA2587926A1 (en) | 2006-06-01 |
NZ555566A (en) | 2009-12-24 |
US20060258662A1 (en) | 2006-11-16 |
IL183318A0 (en) | 2007-09-20 |
WO2006058120A1 (en) | 2006-06-01 |
EP1814882A1 (en) | 2007-08-08 |
NO20073140L (no) | 2007-06-20 |
AU2005309566A1 (en) | 2006-06-01 |
RU2007123360A (ru) | 2009-01-27 |
JP2008520745A (ja) | 2008-06-19 |
US20110081364A1 (en) | 2011-04-07 |
EP2316835A1 (en) | 2011-05-04 |
JP2008520738A (ja) | 2008-06-19 |
MX2007006103A (es) | 2007-07-20 |
RU2394825C2 (ru) | 2010-07-20 |
EP1814883A1 (en) | 2007-08-08 |
CN101098872B (zh) | 2012-09-05 |
US8372835B2 (en) | 2013-02-12 |
AU2005309616A1 (en) | 2006-06-01 |
US7795259B2 (en) | 2010-09-14 |
CA2587894A1 (en) | 2006-06-01 |
CN101098872A (zh) | 2008-01-02 |
US20060122185A1 (en) | 2006-06-08 |
JP2009024024A (ja) | 2009-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200704888B (en) | Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases | |
TWI372624B (en) | Azaindoles useful as inhibitors of jak and other protein kinases | |
SI1811998T1 (sl) | Triazoli uporabni kot inhibitorji proteinskih kinaz | |
PT1562589E (pt) | Diaminotriazoles úteis como inibidores de proteína-quinases | |
HK1099764A1 (en) | Quinoxalines useful as inhibitors of protein kinases | |
EP1931205A4 (en) | TRANSGLUTAMINASE INHIBITORS AND METHOD OF USE THEREOF | |
PT1664043E (pt) | Composições úteis como inibidores de proteínas quinases | |
HK1129298A1 (en) | Dihydrodiazepines useful as inhibitors of protein kinases | |
IL179613A0 (en) | Compounds and compositions as protein kinase inhibitors | |
PL1713806T3 (pl) | Związki i kompozycje jako inhibitory kinaz białkowych | |
IL182687A0 (en) | Compounds and compositions as protein kinase inhibitors | |
PL2305250T3 (pl) | Pochodne benzimidazolu i ich zastosowanie jako inhibitorów kinaz białkowych | |
IL194699A0 (en) | Tetrahydropteridines useful as inhibitors of protein kinases | |
EP1981888A4 (en) | TYROSINE KINASE INHIBITORS AND USES THEREOF | |
SI2332940T1 (sl) | Azaindoli, uporabni kot inhibitorji jak in drugih protein-kinaz | |
IL178908A0 (en) | Benzotriazine inhibitors of kinases | |
EP1812012A4 (en) | PROTEIN TYROSINE PHOSPHATASE INHIBITOR AND METHOD FOR THEIR USE | |
EP1877424A4 (en) | INHIBITORS OF PROTEIN KINASES AND USES THEREOF | |
EP1765820A4 (en) | COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF PROTEIN KINASES | |
EP1922086A4 (en) | TARGETED PROTEIN KINASE C HEMMER AND ITS USES | |
ZA200806871B (en) | Dihydrodiazepines useful as inhibitors of protein kinases | |
IL181819A0 (en) | Enzyme inhibitors and uses thereof | |
EP1883404A4 (en) | P38 INHIBITORS AND METHODS OF USE | |
ZA200703130B (en) | Compounds and compositions as protein kinase inhibitors | |
ZA200700751B (en) | Azalndoles useful as inhibitors of protein kinases |